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are a major tool to reduce morbidity.5,6 South Africa is a signatory of 
World Health Assembly Resolution 54.19 that calls on member 
states to take effective steps to control schistosomiasis and soil-
transmitted helminthiasis. This calls for non-selective treatment of all 
children at risk, and targets the year 2010 for regular chemotherapy 
programmes.6
The importance of such preventive policies is because praziquantel 
kills the adult schistosoma but not the ova. The ova cause granulomas, 
the entry and exit for the transmission of HIV, and possibly act as a 
co-factor in cervical carcinogenesis.3
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To the Editor: While working for the National Pathology Group 
(NPG) to help them understand the pathology cost trends in medical 
schemes from publicly available data, we came across two interesting 
relationships between costs in the private industry.  
Medical schemes have lamented the inflation increase in pathology 
costs over the past 5 years. This gave rise to a Discovery Health 
advertisement in a medical publication, ‘Working together we can 
ensure a strong, sustainable health care system’, where the increase in 
pathology costs was raised as a problem and doctors were requested 
to assist Discovery Medical Scheme manage these costs. In reviewing 
pathology trends against other trends within Discovery, using data 
obtained from the Council for Medical Schemes, we established the 
following.
Fig. 1 clearly shows that Discovery Medical Scheme experienced 
greater pressure in average beneficiary per annum (pabpa) trends for 
medical specialists (this measure excludes all radiology, pathology 
and anesthesiology) and general practitioners in the 5-year period 
than the scheme experienced in pathology costs. This graph supports 
the Lifechoice view that it is the increase in members accessing 
specialist care that drives pathology, radiology, hospital and other 
benefit expenditure areas.
Comparing Discovery Medical Scheme’s non-health care costs 
(NHCs) against the other South African medical schemes reveals the 
other interesting cost relationship. 
Fig. 2. shows that the NHCs of Discovery Medical Scheme, the 
biggest scheme in South Africa, are significantly higher than the 
rest of the industry excluding Discovery. The difference shown is 
more than the amount Discovery Medical Scheme pays the general 
practitioners who look after its members and what it spends on 
pathology. This cost comparison cannot be ignored.
This difference may also be seen in some other open medical 
schemes, and some argue that open medical scheme and closed 
medical scheme NHCs are not comparable (we are not convinced that 
consumers would see this argument as relevant).  
Lifechoice, together with one of South Africa’s most respected 
independent health actuaries, have researched the cost drivers in 
South African health going back to 1980. The costs of belonging to 
medical schemes have increased over 400% in real terms since 1980. 
The five most significant cost drivers seen over this period are:
1.   A lack of focus by medical schemes on primary health care.
2.    A focus on specialist curative care and the costs associated with 
this.
3.    The hospital admission and other costs that result from the focus 
on specialist care.
4.   NHCs. 
5.    Missing medical scheme legislation – the current legislation is 
only sustainable if all working South Africans are compelled 
to belong to a medical scheme (so-called mandatory cover), 
prescribed minimum benefits include primary health care 
benefits, and clarity is provided regarding exactly what is covered 
by prescribed.
We must indeed start working together to ensure sustainable 
health care. It is critical that as we do this, we focus on all of the above 
areas. Until we move towards models that support primary health 
care and fund primary health care properly, we will continue to see 
costs escalate.
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Fig. 1. Discovery Medical Scheme – cumulative increases per average benefi-
ciary per annum since 2005.Fig. 1. Discovery Medical Scheme 
since 2005.   














 
– cumulative increases per average beneficiary per annum 









Fig. 2. Non-health care costs (nominal values) since 2005.
Fig. 2. Non-health care costs (nominal values) since 2005.
















 
















 
CORRESPONDENCE
